Nivolumab cost effective for mRCC in China, not in USANo Abstract available for this article.doi:10.1007/s40274-017-3888-9NoneSpringer International PublishingPharmacoeconomics & Outcomes News
Cost-effectiveness of nivolumab in patients with NSCLC in the United States. Am J Manag Care. 2021;27(8):e254–60. Article Google Scholar Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–24. Article...
Nivolumab in com- bination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2969–2979. 7. Calikusu Z, Yildirim Y, Akcali Z, et al. The effect of HER2 expression on cisplatin-based chemotherapy in ...
Nivolumab and Olaparib. Hosp Pharm. 2013; 50(5):356-366. www.thomasland.com/hpjdig/hpj5005-356.pdf. Accessed February 19, 2017 André P, Cisternino S, Roy AL, Chiadmi F, Schlatter J, Agranat P, et al. Stability of Oxaliplatin in infusion bags containing ...
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?Lung neoplasmsCanadaCost-effectiveness analysis
Adjuvant nivolumab is currently used for patients with completely resected (R0) EC/GEJC who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. This study aimed to determine the cost effectiveness of nivolumab in this indication in France according to the collective perspective ...
12-monthly PET/CT imaging was associated with a 4% increase in correctly diagnosed and treated distant disease; a 0.5% increase with 6-monthly imaging and 1% increase with 3-monthly imaging. The incremental cost-effectiveness ratio (ICER) of 12-monthly PET/CT surveillance imaging was AUD 34,...
Retinal pigment epithelial (RPE) cells located in the posterior segment of the eye are also immune privileged cells and have a T-cell-suppressing effect. However, RPE cells, which are known to be immunogenic cells, have major histocompatibility complex (MHC) expression and experience rejection ...